Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
-
J Cardiovasc Magn Reson · Jan 2008
Comparative StudyCardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction.
The acute coronary syndrome diagnosis includes different classifications of myocardial infarction, which have been shown to differ in their pathology, as well as their early and late prognosis. These differences may relate to the underlying extent of infarction and/or residual myocardial ischemia. The study aim was to compare scar and ischemia mass between acute non-ST elevation myocardial infarction (NSTEMI), ST-elevation MI with Q-wave formation (Q-STEMI) and ST-elevation MI without Q-wave formation (Non-Q STEMI) in-vivo, using cardiovascular magnetic resonance (CMR). ⋯ Prior to revascularisation, the ratio of scar to ischemia differs between NSTEMI, Non-Q STEMI and Q-STEMI, whilst the combined scar and ischemia mass is similar between these three types of MI. These results provide in-vivo confirmation of the diverse pathophysiology of different types of acute myocardial infarction and may explain their divergent early and late prognosis.
-
J Cardiovasc Magn Reson · Jan 2008
Ventricular assist device implant (AB 5000) prototype cannula: in vitro assessment of MRI issues at 3-Tesla.
To evaluate MRI issues at 3-Tesla for a ventricular assist device (VAD). ⋯ The results of this investigation demonstrated that it would be acceptable for a patient with this VAD (AB5000 Ventricle with a prototype Nitinol wire-reinforced In-Flow Cannula and Out-Flow Cannula attached) to undergo MRI at 3-Tesla or less. Notably, it is likely that the operation console for this device requires positioning a suitable distance (beyond the 100 Gauss line or in the MR control room) from the 3-Tesla MR system to ensure proper function of the VAD.
-
J Cardiovasc Magn Reson · Jan 2008
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.
Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10-15% when administered sequentially following anthraycline chemotherapy. Little is known about the utility of cardiac magnetic resonance (CMR) in the assessment of trastuzumab mediated cardiomyopathy. ⋯ LGE-CMR is a novel way of detecting early changes in the myocardium due to trastuzumab induced cardiotoxicity.